Long-term assessment of visual and refractive outcomes of laser in situ keratomileusis for hyperopia using the AMARIS® 750S Excimer laser

Abstract

Purpose. - To evaluate the long-term efficacy and safety of hyperopic laser in situ keratomileusis (LASIK) using the AMARIS (R) 750S (Schwind, Eye-tech-solutions, GmbH) excimer laser. Methods. - The medical records of one hundred eleven eyes of 62 patients who underwent LASIK for hyperopia using the AMARIS (R) 750S excimer laser were reviewed retrospectively. Patients were divided into three groups based on preoperative spherical equivalent (SE) refraction: low hyperopia (less than +2.50 diopters [D]), moderate hyperopia (+2.75D to +4.00D), and high hyperopia (over +4.00D). Uncorrected and best corrected visual acuity (BCVA), long-term stability of refraction, and complications were evaluated. Results. - Of the entire sample, the mean preoperative SE was +3.64D +/- 1.22D. The mean age was 37.4 +/- 11.2 years (20-59). The mean follow-up for all eyes was 51 months. At the last visit, the mean SE was +0.85D +/- 0.34D (SD) in the low hyperopia group, +1.09D +/- 0.43D in the moderate hyperopia group, and +1.63D +/- 0.47D in the high hyperopia group. (+1.15D +/- 0.49D overall). Preoperative uncorrected visual acuity (UCVA) was 0.52 +/- 0.34 logMAR and increased to 0.18 +/- 0.15 logMAR at 4 years follow-up (P < 0.01). There was no statistically significant difference between preoperative and postoperative BCVA. The UCVA was 0.30 logMAR or better in 100% of eyes in the low hyperopia group, 93.7% in the moderate hyperopia group, and 69.9% in the high hyperopia group (%89.2 overall). Conclusions. - LASIK is safe and effective for correcting hyperopia in the short term; however, the efficacy of the procedure is limited in the patients with high hyperopia and longer follow-up. (C) 2019 Elsevier Masson SAS. All rights reserved.